<DOC>
	<DOCNO>NCT02567955</DOCNO>
	<brief_summary>A ninevalent HPV vaccine ( Gardasil-9 ) recently approve clinical use . No data immunogenicity safety interchangeable use ninevalent bivalent vaccine ( Cervarix ) available . The main objective study assess immunogenicity ninevalent bivalent HPV vaccine administer 9-10-year-old girl boy accord 0-6 month schedule .</brief_summary>
	<brief_title>Immunogenicity Safety Gardasil-9 Cervarix</brief_title>
	<detailed_description>The proportion subject detectable antibody antibody geometrical mean titer 9 HPV genotype include Gardasil-9 vaccine assess 1 6 month post-first dose 1 , 18 36 month post-second dose vaccine .</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>910yearold girl boys previously receive HPV vaccine immunosuppressed know allergy vaccine component</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>HPV vaccine , interchangeable use</keyword>
</DOC>